sCD146 CLIA Assay
Biomarker (Cardiovascular/Kidney)
Commercial (Approved)Launched
Key Facts
Indication
Biomarker (Cardiovascular/Kidney)
Phase
Commercial (Approved)
Status
Launched
Company
About YHLO Biotech
A publicly listed Chinese IVD leader with a broad portfolio of over 300 diagnostic tests across autoimmunity, infectious disease, and reproductive health, operating globally.
View full company profile